Clinical Trial Update: Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial [Phase 2]

View source ↗

Summary

Phase 2 CHI SQUARE trial evaluated CER-001 for efficacy and safety in patients with acute coronary syndrome and atherosclerosis. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Syndrome

Drugs mentioned

• CER-001

Snippet

Sponsor: Cerenis Therapeutics, SA | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED